Corcept Therapeutics Inc (CORT) stock
CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30537% above fair value
$70.07+0.85 (+1.23%)
Close on Nov 17, 2026Market cap $7.57BP/E 166.8Yield –
Corcept Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Corcept Therapeutics's pe ratio was 177.4× on Nov 11, 2026, against 91.3× a year earlier. Over the last 5 years it ranged from 20.3× to 327.1×, with a median of 36.5×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 177.4× | +137.4 |
| 2025 | Dec 31, 2025 | 40.0× | +0.0 |
| 2024 | Dec 31, 2024 | 40.0× | −0.1 |
| 2023 | Dec 29, 2023 | 40.1× | +19.8 |
| 2022 | Dec 30, 2022 | 20.3× | −3.5 |
| 2021 | Dec 31, 2021 | 23.9× | −5.5 |
| 2020 | Dec 31, 2020 | 29.4× | +12.6 |
| 2019 | Dec 31, 2019 | 16.8× | +5.6 |
| 2018 | Dec 31, 2018 | 11.2× | −51.0 |
| 2017 | Dec 29, 2017 | 62.3× | −119.2 |
| 2016 | Dec 30, 2016 | 181.5× | – |
See a number that looks wrong?